In fact, there are several ongoing clinical trials in the United States investigating GRP78, PERK, and XBP1-targeted therapeutics for cancer as well as for rheumatoid arthritis and type 2 diabetes (clinicaltrials.gov). The gene discussed is EIF2AK3; the disease is cancer.